NetworkNewsBreaks – AnPac Bio-Medical Science Co
Post# of 61
(Total Views: 238)
Posted On: 10/22/2021 3:26:32 PM
NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is combined with protein-based biomarker tests to obtain even more comprehensive information, can be used to obtain more comprehensive data and information,” explains a recent article. “Unlike most liquid-based cancer screening and detection methods, the CDA platform from AnPac Bio focuses on assessing the existing protein-based biomarkers with biophysical properties of the blood tested to signal the lead-up to serious health problems, including cancer… assessing cancer risk and its type, and predicting where the risk is highest in the future through a standard blood test. CDA is powered by a database of over 220,000 samples and cases, allowing it to serve as a new approach to disease and cancer screening.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is combined with protein-based biomarker tests to obtain even more comprehensive information, can be used to obtain more comprehensive data and information,” explains a recent article. “Unlike most liquid-based cancer screening and detection methods, the CDA platform from AnPac Bio focuses on assessing the existing protein-based biomarkers with biophysical properties of the blood tested to signal the lead-up to serious health problems, including cancer… assessing cancer risk and its type, and predicting where the risk is highest in the future through a standard blood test. CDA is powered by a database of over 220,000 samples and cases, allowing it to serve as a new approach to disease and cancer screening.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)